Related news from
Tue, 23 Apr 2024 12:00:00 +0000	Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph
Thu, 11 Apr 2024 14:12:44 +0000	Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Fri, 05 Apr 2024 13:40:12 +0000	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Wed, 20 Mar 2024 13:40:12 +0000	Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
Mon, 04 Mar 2024 17:00:12 +0000	Aclaris (ACRS) Upgraded to Buy: Here's Why Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mon, 04 Mar 2024 14:40:13 +0000	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Fri, 01 Mar 2024 12:29:59 +0000	Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations Aclaris Therapeutics ( NASDAQ:ACRS ) Full Year 2023 Results Key Financial Results Revenue: US$31.2m (up 5.0% from FY...
Thu, 29 Feb 2024 10:39:14 +0000	Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51% The latest analyst coverage could presage a bad day for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ), with the analysts...
Tue, 27 Feb 2024 14:35:02 +0000	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tue, 27 Feb 2024 12:00:00 +0000	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. “Returnin
Tue, 27 Feb 2024 11:51:37 +0000	Can Aclaris Therapeutics (NASDAQ:ACRS) Afford To Invest In Growth? We can readily understand why investors are attracted to unprofitable companies. For example, although...
Tue, 20 Feb 2024 15:00:55 +0000	Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu, 15 Feb 2024 15:00:49 +0000	Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 17 Jan 2024 16:14:00 +0000	Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
Tue, 16 Jan 2024 12:00:00 +0000	Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review - Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review o
Wed, 10 Jan 2024 12:00:00 +0000	Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis - ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an i
Tue, 19 Dec 2023 21:01:00 +0000	Aclaris Therapeutics Provides Corporate Update - ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates. First, Aclaris announced the publication of the Phase 2a trial results of ATI-17
Tue, 05 Dec 2023 21:01:00 +0000	Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitini
Mon, 04 Dec 2023 14:35:02 +0000	Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Thu, 16 Nov 2023 14:35:04 +0000	Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS) Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.